Protagonist Therap

Forecast & Rating13 analysts currently cover Protagonist Therap, with about 92.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $133.31, about 2.6% downside from the current price of $136.84. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 67.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Protagonist Therap closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.